Loading clinical trials...
Loading clinical trials...
Randomized Trial of Epirubicin and Cyclophosphamide Followed by Docetaxel Against Docetaxel and Cyclophosphamide in Patients With TOP2A Normal Early Breast Cancer
Conditions
Interventions
Epirubicin, cyclophosphamide and docetaxel
docetaxel, cyclophosphamide
Locations
13
Denmark
Dept. of Oncology; Aalborg Sygehus
Aalborg, Denmark
Dept. of Oncology; Århus Sygehus
Aarhus, Denmark
Dept. of Oncology; Rigshospitalet
Copenhagen, Denmark
Dept. of Oncology; Sydvestjysk Sygehus Esbjerg
Esbjerg, Denmark
Dept. of Oncology; Herlev Hospital
Herlev, Denmark
Dept. of Oncology; Regionshospitalet Herning
Herning, Denmark
Start Date
June 1, 2008
Primary Completion Date
January 1, 2013
Completion Date
January 1, 2013
Last Updated
April 5, 2018
NCT07191730
NCT06312176
NCT06797635
NCT07003841
NCT07396766
NCT06443645
Lead Sponsor
Danish Breast Cancer Cooperative Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions